Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Free Cash Flow (2023 - 2025)

Historic Free Cash Flow for Inhibrx Biosciences (INBX) over the last 3 years, with Q3 2025 value amounting to -$33.8 million.

  • Inhibrx Biosciences' Free Cash Flow fell 1082.94% to -$33.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$143.4 million, marking a year-over-year increase of 3282.58%. This contributed to the annual value of -$197.0 million for FY2024, which is 45.27% up from last year.
  • According to the latest figures from Q3 2025, Inhibrx Biosciences' Free Cash Flow is -$33.8 million, which was down 1082.94% from -$30.0 million recorded in Q2 2025.
  • Inhibrx Biosciences' 5-year Free Cash Flow high stood at -$30.0 million for Q2 2025, and its period low was -$64.2 million during Q1 2024.
  • Moreover, its 3-year median value for Free Cash Flow was -$43.7 million (2024), whereas its average is -$45.8 million.
  • Over the last 5 years, Inhibrx Biosciences' Free Cash Flow had its largest YoY gain of 4886.21% in 2025, and its largest YoY loss of 1082.94% in 2025.
  • Inhibrx Biosciences' Free Cash Flow (Quarter) stood at -$60.3 million in 2023, then rose by 27.42% to -$43.7 million in 2024, then rose by 22.64% to -$33.8 million in 2025.
  • Its last three reported values are -$33.8 million in Q3 2025, -$30.0 million for Q2 2025, and -$35.9 million during Q1 2025.